Navigation Links
New study indicates smallpox vaccination effective for decades
Date:3/20/2009

New York, December 1, 2008 Although naturally occurring smallpox was eradicated in 1977, there is concern that bioterrorists might obtain smallpox from a laboratory and release it into the population. Under such circumstances, the supply of smallpox vaccine may be insufficient for universal administration. In a study published in the December 2008 issue of The American Journal of Medicine, researchers found that lifetime protection is obtained from just one vaccination, even when that vaccination occurred as much as 88 years ago. They conclude that in the event of a smallpox bioterrorist attack, vaccinia smallpox vaccine should be used first on individuals who have not been vaccinated previously.

Examining 246 participants of the Baltimore Longitudinal Study of Aging, investigators from the National Institute on Aging and the National Institute of Allergy and Infectious Diseases, National Institutes of Health found permanent immunity was conferred by vaccination or by survival from an active smallpox infection. In the sample, 209 subjects were vaccinated one or more times 13 to 88 years prior to the study; an additional 18 had had childhood smallpox, and 29 with no history of vaccination or smallpox were included.

Although the vaccinia virus vaccine was used since the late 18th century, routine vaccination was discontinued more than 30 years ago in many countries. Most Americans under 35 have never been vaccinated and most over 35 have not received booster immunizations since the early 1970s. If a bioterrorist attack were to occur, it would be critical to know who already had effective immunity and would not need to be vaccinated, leaving another dose available for someone else.

Current recommendations relating to smallpox vaccination has been that people with repeated exposure to smallpox, for example travelers to endemic areas, should be revaccinated every five years. This study suggests that such reimmunizations may not be necessary because multiple vaccinations achieve only marginally higher levels of antibody and virus neutralizing activity than single vaccination.

Writing in the article, Dan L. Longo, MD, National Institute on Aging, states "A major question posed today is whether those individuals vaccinated 40 or more years ago would be protected in the event of smallpox exposure. This may be a critical question because the availability of smallpox vaccines is limited and currently inadequate for a mass inoculation program. We found that vaccinated subjects maintain what appear to be protective levels of neutralizing antibodies to vaccinia indefinitely and do not require booster vaccinations even if they are many decades removed from primary vaccination. These data imply that limited supplies of vaccine can be more usefully applied to individuals who have never been vaccinated, primarily individuals born after 1972."


'/>"/>

Contact: Pamela Poppalardo
ajmmedia@elsevier.com
212-633-3944
Elsevier Health Sciences
Source:Eurekalert

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , February 4, 2016 - New FDA action ... - New FDA action date of July 22, ... July 22, 2016   - ... in the past decade indicated for the treatment of signs and symptoms of ... has the potential to be the only product approved in the U.S. in ...
(Date:2/4/2016)... -- Beike Biotechnology, the Shenzhen ... in late 2015 to mark their successful combined efforts ... --> --> The signing, ... Therapy" was hosted by the Shenzhen Cell Bank and ... Beike Biotechnology Co., Ltd. Shenzhen,s ...
(Date:2/4/2016)... 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... to be held February 8-9, 2016, at the Waldorf ... Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ContraVir, ...
(Date:2/4/2016)... 2016 Strasbourg, France , ... --> Strasbourg, France , to the US ... is pleased to announce that it acted as an advisor ... in Strasbourg, France , to the US ... --> Transgene (Euronext: TNG), a member of ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
Breaking Biology News(10 mins):